|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We report herein, in analyses of mice implanted with various tumor cell lines, soluble IL-15/IL-15Rα complexes (sIL-15 complexes) are abundant in the interstitial fluid of tumors with expression preceding the infiltration of tumor-infiltrating lymphocytes.
|
30587590 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In WSC, we identified an association between the plasmatic ANGPTL-4, IL-15, and IL-10 in tumor and IL-15 in MES.
|
31741709 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DNTs recognize tumors via innate receptors which can be up-regulated by IL-15.
|
30670085 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We utilized an IL15 superagonist to enhance the development of antigen-specific immunity initiated by the neoepitope vaccine, PD-L1 blockade to reduce tumor immunosuppression, and a tumor-targeted IL12 molecule to facilitate T-cell function within the tumor microenvironment.
|
31292145 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that MeVac encoding interleukin-15 may mediate enhanced T and NK cell responses and thus increase the therapeutic efficacy, especially in NK cell-controlled tumors.
|
31623390 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In an orthotopic PDX model, animals receiving chemoimmunotherapy with an anti-GD2 antibody, GM-CSF, and a soluble IL15/IL15Rα complex had greater tumor regression than did those receiving chemotherapy alone (<i>P</i> = 0.012) or combined with anti-GD2 antibody and GM-CSF with (<i>P</i> = 0.016) or without IL2 (<i>P</i> = 0.035).
|
31455682 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, an immunosuppressive tumor environment in nonmuscle invasive bladder cancer that have failed prior BCG may respond better to interleukin-15 immunotherapy compared with tumors without an immunosuppressive environment.
|
31107371 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The previously reported format consisted of a tumor-directed antibody (scFv), IL15 linked to an IL15Rα-fragment (RD), and the extracellular domain of 4-1BBL, where noncovalent trimerization of 4-1BBL into its functional unit led to a homotrimeric molecule with 3 antibody and 3 IL15-RD units.
|
31040163 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor rechallenge experiments <i>in vivo</i> further highlighted the role of IL15 in promoting enhanced CAR-T antitumor activity and survival, both in the peripheral blood and tissues.
|
30617136 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of tumor-bearing mice with DMA-pIL15 complex significantly inhibited tumor growth in both subcutaneous and peritoneal models <i>in vivo</i> by inhibiting angiogenesis, promoting apoptosis, and reducing proliferation through activation of the host immune system.
|
30026861 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
From a biological perspective, it has been demonstrated that HR2A could have a beneficial effect on CRC for many reasons: i) promotion of peri-tumoral lymphocyte growth and improvement of immune response against the tumor, ii) suppression of adhesion molecules which might favor metastasis, iii) anti-angiogenetic activity (reduction of VEGF), iv) increased production of some cytokines which may counteract tumor growth, such as tumor necrosis factor (TNF) alpha, interleukin (IL)-10 and IL-15.
|
26996193 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The cumulative result of BRD4 binding was increased expression of tumor-associated genes such as <i>NOTCH1</i> and <i>RBPJ</i>, as well as the interleukin-15 (IL-15) receptor complex, the latter enhancing IL-15 autocrine signaling.
|
29180399 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data strongly indicated that tumor vaccine modified with NDV strain LX/IL(15+7) is a promising agent for cancer immunotherapy.
|
29224228 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In xenograft models, anti-CEA-IL15 was localized in the tumor microenvironment and exhibited more potent antitumor activities than non-targeting IL-15, supporting potential application of this multifunctional fusion molecule in tumor immunotherapy.
|
30214153 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The demonstration that IL-15 can recover hepatic NK cell function following tumor exposure supports its inclusion in immunotherapy strategies.
|
29867983 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Alongside expressing chimeric antigen receptors to overcome immune escape by cancer cells, enhance their recognition, and mediate their killing, NK cells have been genetically modified to enhance their persistence <i>in vivo</i> by the expression of cytokines such as IL-15, avoid functional and metabolic tumor microenvironment suppression, or improve their homing ability, enabling enhanced targeting of solid tumors.
|
30306093 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Signals in the tumor microenvironment may promote this response, including the cytokine IL-15 and stress-associated ligands for activating NK receptors.
|
29311382 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human Gastric Cancer Mesenchymal Stem Cell-Derived IL15 Contributes to Tumor Cell Epithelial-Mesenchymal Transition via Upregulation Tregs Ratio and PD-1 Expression in CD4<sup>+</sup>T Cell.
|
29901436 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a preclinical mouse model of breast cancer, the rate of muscle fatigue was greater in mice exposed to mammary tumour growth for 4 weeks, and this greater muscle fatigue was attenuated in transgenic mice that overexpressed the cytokine IL-15.
|
29582584 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-15 greatly enhanced the therapeutic efficacy of both rituximab and alemtuzumab in tumor models.
|
30373815 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Altogether, our data demonstrated that low doses of chemotherapeutic drugs, by inducing tumor cell senescence and a senescence-associated secretory phenotype, promoted IL15 trans-presentation to NK cells and, in turn, their activation and proliferation, thus enhancing NK cell-tumor immune surveillance and providing new insights for the exploitation of senescence-based cancer therapies.<i></i>.
|
29691234 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, co-expression of IL-15 did not result in elevated regulatory T cell levels in tumor environment measured by flow cytometry.
|
30452438 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although IL-15 enhanced the trastuzumab mediated tumor defense, an unspecific immune stimulation resulted in preterm animal death due to systemic inflammation.
|
27835865 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study has provided preclinical evidence that combined treatment with cytotoxic effector cells and CRAd-CCL20-IL15 may offer alternative treatment options for tumor therapy.
|
28651743 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We previously showed that bioactive IL15 <i>in vivo</i> comprises a stable complex of the IL15 chain with the IL15 receptor alpha chain (IL15Rα), termed heterodimeric IL15 (hetIL15).<b>Experimental Design:</b> We evaluated the effects of the combination regimen ACT + hetIL15 in the absence of lymphodepletion by transferring melanoma-specific Pmel-1 T cells into B16 melanoma-bearing mice.<b>Results:</b> hetIL15 treatment delayed tumor growth by promoting infiltration and persistence of both adoptively transferred Pmel-1 cells and endogenous CD8<sup>+</sup> T cells into the tumor.
|
27986749 |
2017 |